Allogeneic CAR T cells for autoimmune diseases: a glimpse into the future

IF 40.8 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Signal Transduction and Targeted Therapy Pub Date : 2024-10-08 DOI:10.1038/s41392-024-01998-8

Dimitrios Mougiakakos

引用次数: 0

Abstract

In a recent study published in Cell, Wang X et al.¹ reported the first use of allogeneic anti-CD19 CAR T cells in patients with therapy-resistant autoimmune diseases, demonstrating their effectiveness in reducing disease activity, with good tolerability and persistence. These findings suggest that allogeneic CAR T cells could offer a scalable, off-the-shelf treatment option for autoimmune disorders.

Abstract Image

查看原文本刊更多论文

异体 CAR T 细胞治疗自身免疫性疾病：未来一瞥

最近发表在《细胞》（Cell）杂志上的一项研究中，Wang X 等人1 首次报道了异体抗 CD19 CAR T 细胞在治疗耐药的自身免疫性疾病患者中的应用，证明了其在降低疾病活动性方面的有效性、良好的耐受性和持久性。这些研究结果表明，异体 CAR T 细胞可为自身免疫性疾病提供一种可扩展的现成治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Signal Transduction and Targeted Therapy Biochemistry, Genetics and Molecular Biology-Genetics

CiteScore

44.50

自引率

1.50%

发文量

384

审稿时长

5 weeks

期刊介绍： Signal Transduction and Targeted Therapy is an open access journal that focuses on timely publication of cutting-edge discoveries and advancements in basic science and clinical research related to signal transduction and targeted therapy. Scope: The journal covers research on major human diseases, including, but not limited to: Cancer,Cardiovascular diseases,Autoimmune diseases,Nervous system diseases.